0,1
"5.2.7.3	
Alpha 1-blockers + beta-3 agonist
Mechanism of action: Combination therapy consists of an α1-blocker (Section 5.2.1) together with a beta-3-
agonist (Section 5.2.4) as an add-on therapy in males receiving α1-blockers with persisting OAB symptoms.",
Summary of evidence,LE
"Combination treatment with α1-blockers and mirabegron results in a slight decrease of number of 
voids and urgency episodes per day compared with α1-blockers alone.",1b
"Adverse events of both drug classes are seen with combined treatment using α1-blockers and 
mirabegron.",1b
